PT  - JOURNAL ARTICLE
AU  - Liu, Qinghe
AU  - Liu, Zhicheng
AU  - Li, Deqiang
AU  - Gao, Zefei
AU  - Zhu, Junkai
AU  - Yang, Junyan
AU  - Wang, Qiao
TI  - Assessing the Tendency of 2019-nCoV (COVID-19) Outbreak in China
AID  - 10.1101/2020.02.09.20021444
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.02.09.20021444
4099  - http://medrxiv.org/content/early/2020/02/22/2020.02.09.20021444.short
4100  - http://medrxiv.org/content/early/2020/02/22/2020.02.09.20021444.full
AB  - Since December 8, 2019, the spread of COVID-19 is increasing every day. It is particularly important to predict the trend of the epidemic for the timely adjustment of the economy and industries. We proposed a Flow-SEHIR model in this paper, based on which we further analyzed the trends of 2019-nCoV (COVID-19) in China.The results show that the basic reproductive numbers R0 of COVID-19 is 3.56 (95% CI: 2.31 – 4.81). The number of daily confirmed new cases reaches the inflection point on Feb. 6 – 10 outside Hubei. For the maximum of infected cases number, the predicted peak value in China except Hubei was estimated to be 13806 (95% CI: 11926 - 15845). The peak arrival time is on March 3 - 9. The temporal number of patients in most areas of China outside Hubei will peak from March 12 to March 15. The peak values of more than 73.5% provinces or regions in China will be controlled within 1000. According to Flow-SEHIR model and estimations from the data of evacuation of nationals from Wuhan, the peak cumulative number of patients in Hubei was estimated to be 403481 (95% CI: 143284 – 1166936).Competing Interest StatementThe authors have declared no competing interest.Funding Statementno funding supportAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data are publicly available from the network http://qianxi.baidu.com/ http://www.nhc.gov.cn http://ynswsjkw.yn.gov.cn/wjwWebsite/web/index http://wjw.beijing.gov.cn/ http://wjw.hubei.gov.cn/ 2019-nCoV2019 Novel CoronavirusCIConfidence IntervalCOVID-19Coronavirus Disease 2019NCPNovel Coronavirus PneumoniaSARS-CoV-2Severe Acute Respiratory Syndrome Coronavirus 2SEIR modelSusceptible-Exposed-Infectious-Recovered model.